PHI BIOMED LEADING THE FUTURE OF SMART NANOMEDICINES

HOME > R&BD > Core Technology

Core Technology

CB[6]/DAH-HA Hydrogels Encapsulating MSCs
Contact Information
1 Company PHI BioMed, Korea
2 Manager Hye Ryoung Lee, MBA (aosora2001@yahoo.com)
3 Web Page http://www.phibiomed.co.kr
Researcher
4 Institute (Researcher) POSTECH (Prof. Sei Kwang Hahn)
5 Web Page http://bnl.postech.ac.kr
Technology
6 Title CB[6]/DAH-HA Hydrogels Encapsulating MSCs
7 Composition Hyaluronic Acid, Flt1 Cucurbituril[6], Mesenchymal stem cells(MSCs), Adenovirus, Chemical drugs
8 Application
  • Cancer therapy
  • Stroke, limb ischemia
9 Competitive Advantage
  • Non-toxic, stable, in situ forming hydrogel to encapsulate engineered MSCs (eMCSs)
  • Long-term transgene expression of engineered MSCs
10 Stage of Development Preclinical
11 Data Files
  • In Vitro transgene expression ability
  • In Vivo cell viability in mice
  • In Vivo hydrogel degradation data in mice
  • In Vivo cancer therapy in mice (single, repeated injection)
12 Test Model Drug Dexamethasone, Retinoic acid, IL-12 expressing MSCs
13 Representative Figure [ACS Nano 6, 2960 (2012)]
Intellectual Property
14 Domestic Patents filed/granted Patent No. 10-1201473, 2012-0145758
15 International(PCT) Patents filed/granted US 13/362,205
16 Ownership PHI BIOMED
17 Proposal Type Clinical Co-development/Licensing Out
TOP